LYSAKER, NORWAY--(Marketwire - August 31, 2008) - Pronova BioPharma ASA (OSE: PRON.OL) (“Pronova BioPharma” or the “company”) announces that the Phase III outcome trial GISSI-Heart Failure demonstrated that Omacor® reduced mortality and morbidity in patients with congestive heart failure (CHF). Both primary endpoints were met in the 7000 patient trial. The results were presented today at the European Society of Cardiology (ESC) Hot Line session in Munich, Germany. The findings were also published in The Lancet.
